RevolutionLogo.png
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 03, 2021 23:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock...
RevolutionLogo.png
Revolution Medicines Announces Proposed Public Offering of Common Stock
February 01, 2021 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common...
22157.jpg
Worldwide Indsutry for KRAS Inhibitors to 2025 - Players Include Amgen, Mirati Therapeutics & Revolution Medicines Among Others
January 06, 2021 10:53 ET | Research and Markets
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering. The...
RevolutionLogo.png
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 12, 2020 07:30 ET | Revolution Medicines, Inc.
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Programs for Five Targets...
RevolutionLogo.png
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 24, 2020 09:45 ET | Revolution Medicines, Inc.
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...
RevolutionLogo.png
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 12, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 16, 2020 09:00 ET | Revolution Medicines, Inc.
Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON) REDWOOD CITY, Calif., Sept. 16,...
RevolutionLogo.png
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 19, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
May 14, 2020 16:05 ET | Revolution Medicines, Inc.
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of SHP2 Inhibitor (RMC-4630) Against KRAS Mutant Lung Cancers Preclinical...
RevolutionLogo.png
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 29, 2020 08:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...